In our previous studies, we have demonstrated that combined treatment of MAPK/ERK pathway inhibitors with topoisomerase II inhibitor is highly synergistic and enhances reactive oxygen species (ROS) production, leading to apoptosis in leukemia cells [6,7]. Here, MAPK1 is linked to leukemia.